<DOC>
	<DOCNO>NCT01751191</DOCNO>
	<brief_summary>Background : In patient cirrhosis secondary prevention variceal rebleeding non-selective beta-blockers ( NSBBs ) , risk rebleeding death markedly higher fail achieve good hemodynamic response ( HVPG reduction ≥20 % baseline value ≤12mmHg ) . However substantial proportion non-responders never rebleed , thus appear protect NSBBs although non-detected HVPG response . This low sensitivity hamper risk stratification diminishes cost-effectiveness assess hemodynamic response NSBBs . This particularly relevant prevention rebleeding since scenario risk rebleeding portal hypertension relate complication high , call early institution effective therapy . Baseline HVPG bear prognostic significance regard risk develop varix , decompensation , hepatocellular carcinoma death1,2,7,8,18-27 . However , study investigate whether add data baseline HVPG may improve sensitivity criterion define good poor hemodynamic response . Hypothesis : Adding data baseline HVPG may improve sensitivity criterion define good poor hemodynamic response . Objective : Exploring prognostic value basal HVPG good discriminate non-responders re-bleed prophylactic treatment NSBBs . Methods : Observational cohort study . Training set : patient two longitudinal study conduct Hepatic Hemodynamic laboratory Hospital Clínic Barcelona ass prognostic value HVPG change continuous therapy NSBBs prevent variceal rebleeding . Validation set chronic hemodynamic response : patient two longitudinal study conduct Hepatic Hemodynamic laboratory Hospital de Sant Pau Barcelona ass prognostic value HVPG change continuous therapy NSBBs prevent variceal rebleeding ; third cohort compose patient undergo acute hemodynamic response intravenous propranolol study . All patient receive preplanned follow-up outpatient clinic 1 , 3 , 6 month , every 6 month thereafter original study . End-point : bleeding portal hypertensive source ( esophago-gastric varix portal hypertensive gastropathy ) ( define accord Baveno criterion 32 ) , death liver transplantation . Ethical aspect : All patient give write informed consent use data original study .</brief_summary>
	<brief_title>HVPG Rebleeding Risk Stratification</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Liver Cirrhosis Admission bleed esophageal varix previous 7 day Baseline HVPG &gt; 12 mmHg Subsequent longterm treatment NSBB ( propranolol nadolol ) Second measurement HVPG 13 month therapy Hepatocellular carcinoma Portal vein thrombosis Contraindications betablockers Cholestatic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>